Myeloid Malignancies Mutation Panel by Next Generation Sequencing
Also known as: MYE NGS
Use
This test is used to assess for somatic molecular variants in myeloid malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN). These variants can have prognostic and/or therapeutic significance. This panel targets somatic mutations including substitutions and insertions/deletions, but it does not include copy number variants (CNVs). For comprehensive testing including CNVs, a related panel should be considered. The presence of certain mutations may lead to changes in clinical management and therapeutic decisions.
Special Instructions
The test does not detect inherited or germline variants. For hereditary or familial cancer concerns, additional clinical evaluation and genetic counseling are recommended. Specimen source is required for test processing. Specimens from New York clients will be sent to a New York state-approved laboratory.
Limitations
This test does not include copy number variants. Variants outside the targeted regions or below the limit of detection are not identified. Some regions may not be sequenced due to technical limitations, pseudogenes, or repetitive regions. It cannot distinguish between somatic and germline variants. Variants in regions not included in the preferred transcript may also be missed.
Methodology
NGS (Targeted)
Biomarkers
LOINC Codes
- 11526-1
- 31208-2
- 35474-6
- 44833-2
Result Turnaround Time
12-14 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1.5 mL
Container
Lavender (EDTA) or Green (sodium heparin)
Storage Instructions
Refrigerated
Causes for Rejection
Serum, plasma, grossly hemolyzed specimens, buccal brush or swab, FFPE tissue.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 1 week |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant